Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2024 2
2025 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors.
Möhn N, Narten E, Duzzi L, Thomas J, Grote-Levi L, Beutel G, Fröhlich T, Bollmann BA, Wirth T, von Wasielewski I, Gutzmer R, Heidel F, Pessler F, Zobl W, Schuchardt S, Ivanyi P, Nay S, Skripuletz T. Möhn N, et al. Among authors: frohlich t. Oncoimmunology. 2025 Dec;14(1):2547271. doi: 10.1080/2162402X.2025.2547271. Epub 2025 Aug 16. Oncoimmunology. 2025. PMID: 40817886 Free PMC article.
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123).
Witte D, Pretzell I, Reissig TM, Stein A, Velthaus JL, Alig A, Bohnenberger H, Knödler M, Kurreck A, Sulzer S, Beyer G, Dorman K, Fröhlich T, Hegenberg S, Lugnier C, Saborowski A, Vogel A, Lange S, Reichert M, Flade F, Klaas L, Utpatel K, Becker H, Bleckmann A, Wethmar K, Reinacher-Schick A, Westphalen CB. Witte D, et al. Among authors: frohlich t. J Cancer Res Clin Oncol. 2024 Oct 1;150(10):438. doi: 10.1007/s00432-024-05954-5. J Cancer Res Clin Oncol. 2024. PMID: 39352477 Free PMC article.
The Treatment of Metastatic Renal Cell Carcinoma.
Ivanyi P, Fröhlich T, Grünwald V, Zschäbitz S, Bedke J, Doehn C. Ivanyi P, et al. Among authors: frohlich t. Dtsch Arztebl Int. 2024 Aug 23;121(17):576-586. doi: 10.3238/arztebl.m2024.0147. Dtsch Arztebl Int. 2024. PMID: 39158349 Free PMC article. Review.
Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study.
Wiegmann JP, Fröhlich T, Möhn N, Duzzi L, Narten E, Aurich J, Thomas J, Grote-Levi L, Mahjoub S, Berliner D, Wirth T, Golpon H, Bollmann BA, Von Wasilewski I, Gutzmer R, Heidel FH, Skripuletz T, Beutel G, Ivanyi P; ICOG‐CCCH (Immune Cooperative Oncology Group, Comprehensive Cancer Center Hannover). Wiegmann JP, et al. Among authors: frohlich t. Cancer Med. 2025 Feb;14(3):e70582. doi: 10.1002/cam4.70582. Cancer Med. 2025. PMID: 39865401 Free PMC article.
Neurological management and work-up of neurotoxicity associated with CAR T cell therapy.
Möhn N, Bonda V, Grote-Levi L, Panagiota V, Fröhlich T, Schultze-Florey C, Wattjes MP, Beutel G, Eder M, David S, Körner S, Höglinger G, Stangel M, Ganser A, Koenecke C, Skripuletz T. Möhn N, et al. Among authors: frohlich t. Neurol Res Pract. 2022 Jan 10;4(1):1. doi: 10.1186/s42466-021-00166-5. Neurol Res Pract. 2022. PMID: 35000613 Free PMC article.
Navigating preemptive and therapeutic donor lymphocyte infusions in advanced myeloid malignancies by high-sensitivity chimerism analysis.
Stadler M, Venturini L, Bünting I, Dammann E, Weissinger EM, Schwarzer A, Schultze-Florey C, Ehrlich S, Markel D, Lueck C, Gladysz A, Fröhlich T, Damrah N, Beutel G, Eder M, Ganser A, Hambach L. Stadler M, et al. Among authors: frohlich t. Front Oncol. 2022 Aug 17;12:867356. doi: 10.3389/fonc.2022.867356. eCollection 2022. Front Oncol. 2022. PMID: 36059667 Free PMC article.
Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort Study.
Duzzi L, Möhn N, Narten E, Thomas J, Mahjoub S, Grote-Levi L, Jendretzky K, Nay S, Konen F, Wiegmann J, Beutel G, Fröhlich T, Bollmann BA, Wirth T, von Wasielewski I, Heidel FH, Gutzmer R, Skripuletz T, Ivanyi P; ICOG (Immune Cooperative Oncology Group)-Investigators. Duzzi L, et al. Among authors: frohlich t. Oncol Res. 2026 Apr 22;34(5):17. doi: 10.32604/or.2026.074095. eCollection 2026. Oncol Res. 2026. PMID: 42065045 Free PMC article.